# A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

> **NCT03628079** · PHASE1,PHASE2 · TERMINATED · sponsor: **Repos Pharma** · enrollment: 11 (actual)

## Conditions studied

- Cancer of the Gastrointestinal Tract
- Cancer of Unknown Origin

## Interventions

- **DRUG:** ReposMBZ

## Key facts

- **NCT ID:** NCT03628079
- **Lead sponsor:** Repos Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-25
- **Primary completion:** 2019-01-16
- **Final completion:** 2019-01-16
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of effect
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628079, "A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03628079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*